Susceptibility Testing of Nontuberculous Mycobacteria

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Citation (Scopus)


Nontuberculous mycobacteria (NTM) have emerged as important human pathogens and there are increasing reports of NTM infections worldwide. Both immunosuppressed as well as immunocompetent patients may be affected by these pathogens. Treatment options are mostly guided by antimicrobial susceptibility testing (AST) of the involved NTM. However, since choice of therapy is dependent on NTM species, identification of NTM in a patient is paramount prior to susceptibility testing. Treatment duration may be prolonged and frequently includes using multiple antimicrobials. Currently, however, AST guidelines are limited to select NTM. Additional information is also required on correlation of susceptibility breakpoints with the clinical outcomes; an area that is not well documented in the literature. This chapter provides a summary of available AST guidelines for NTM and explores clinical outcome data with the available AST breakpoints.

Original languageEnglish
Title of host publicationNontuberculous Mycobacteria (NTM)
Subtitle of host publicationMicrobiological, Clinical and Geographical Distribution
Number of pages24
ISBN (Electronic)9780128146934
ISBN (Print)9780128146927
Publication statusPublished - 16 Jan 2019


  • Breakpoint
  • Clinical
  • DST
  • Genotypic
  • Nontuberculous
  • Phenotypic
  • Resistance
  • Susceptibility
  • Treatment


Dive into the research topics of 'Susceptibility Testing of Nontuberculous Mycobacteria'. Together they form a unique fingerprint.

Cite this